U.S. License Holder:
AstraZeneca AB
Date of License:
July-30-2021
Last Update:
Sep-30-2024
FDA-Approved Indications
SAPHNELO (anifrolumab-fnia) is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.